| Primary information |
|---|
| OV_ID | OV_401 |
| Virus Name | Herpes simplex virus |
| Strain | ICP10PK |
| Virus type | DNA |
| Virus family | Herpesviridae |
| Modification in virus genome | Deletion mutant with R1 domain poorly functional in HSV-1 |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | No |
| Source of cell line | NA |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | Xenograft male BALB/c nu/nu mice (subcutaneously injected with 10ⷠA3755 cells in 100 μl) |
| In-vivo virus concentration | 100 μl; 10ⶠPFU on day 7 |
| In-vivo toxicity | NA |
| In-vivo result | On day 29 , tumor growth ratio reached 2 as compared to 13 (tumour growth ratio - dividing each tumour volume measured over time by the initial tumour volume on day 7) |
| Mode of delivery | Intratumorally |
| Pathway induction | NA |
| Immunogenic effect | MICA and TNF-alpha expressions are upregulated |
| Clinical trial | NA |
| PMID | 26602205 |